Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ATRA Stock Forecast 2026-2027
$8.67
Current Price
$78.12M
Market Cap
Buy 3
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ATRA Price Targets
+107.6%
To High Target of $18.00
+49.9%
To Median Target of $13.00
+15.3%
To Low Target of $10.00
ATRA Price Momentum
-15.5%
1 Week Change
-16.7%
1 Month Change
-6.8%
1 Year Change
-52.1%
Year-to-Date Change
-54.7%
From 52W High of $19.15
+121.2%
From 52W Low of $3.92
📊 TOP ANALYST CALLS
Did ATRA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Atara is one of their latest high-conviction picks.
Latest ATRA Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ATRA has a bullish consensus with a median price target of $13.00 (ranging from $10.00 to $18.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $8.67, the median forecast implies a 49.9% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Ilya Zubkov at Freedom Broker, suggesting a 15.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ATRA Analyst Ratings
3
Buy
1
Hold
0
Sell
ATRA Price Target Range
Low
$10.00
Average
$13.00
High
$18.00
Current: $8.67
Latest ATRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ATRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 18, 2026 | Freedom Broker | Ilya Zubkov | Hold | Upgrade | $10.00 |
| May 8, 2026 | Canaccord Genuity | Buy | Upgrade | $N/A | |
| Jan 21, 2026 | Freedom Broker | Sell | Downgrade | $N/A | |
| Jan 13, 2026 | Canaccord Genuity | Hold | Downgrade | $N/A | |
| Dec 19, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 11, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jan 28, 2025 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $N/A |
| Jan 22, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Jan 17, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Dec 20, 2024 | Rodman & Renshaw | Buy | Initiates | $N/A | |
| Nov 13, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Aug 21, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Aug 16, 2024 | Mizuho | Outperform | Upgrade | $N/A | |
| Aug 13, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jul 17, 2024 | Goldman Sachs | Sell | Maintains | $N/A | |
| May 22, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Apr 1, 2024 | Stifel | Hold | Maintains | $N/A | |
| Nov 10, 2023 | Goldman Sachs | Sell | Maintains | $N/A | |
| Nov 9, 2023 | Evercore ISI Group | In-Line | Downgrade | $N/A | |
| Nov 9, 2023 | HC Wainwright & Co. | Neutral | Downgrade | $N/A |
Atara Biotherapeutics, Inc. (ATRA) Competitors
The following stocks are similar to Atara based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Atara Biotherapeutics, Inc. (ATRA) Financial Data
Atara Biotherapeutics, Inc. has a market capitalization of $78.12M with a P/E ratio of 3.8x. The company generates $23.14M in trailing twelve-month revenue with a -40.9% profit margin.
Revenue growth is -99.5% quarter-over-quarter, while maintaining an operating margin of -652.9% and return on equity of -84.9%.
Valuation Metrics
Market Cap
$78.12M
Enterprise Value
$89.67M
P/E Ratio
3.8x
PEG Ratio
0.0x
Price/Sales
3.8x
Growth & Margins
Revenue Growth (YoY)
-99.5%
Gross Margin
+76.0%
Operating Margin
-652.9%
Net Margin
-40.9%
EPS Growth
-99.5%
Financial Health
Cash/Price Ratio
+10.7%
Current Ratio
2.2x
Debt/Equity
-0.3x
ROE
-84.9%
ROA
-3.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Atara Biotherapeutics, Inc. (ATRA) Business Model
About Atara Biotherapeutics, Inc.
What They Do
Develops innovative cell therapies and immunotherapies.
Business Model
Atara Biotherapeutics operates by designing and developing cell and immunotherapies aimed at treating serious diseases, particularly in oncology. The company generates revenue through partnerships, collaborations with research institutions, and potentially from the commercialization of successful therapeutic candidates.
Additional Information
Founded in the United States, Atara Biotherapeutics is positioned in the biopharmaceutical sector, emphasizing scientific innovation to meet critical unmet medical needs. Its focus on advanced cellular and molecular approaches aims to provide significant clinical benefits to patients.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
13
CEO
Dr. Anhco Nguyen Ph.D.
Country
United States
IPO Year
2014
Website
www.atarabio.comAtara Biotherapeutics, Inc. (ATRA) Latest News & Analysis
Latest News
Quick Summary
Quetzal Therapeutics has initiated dosing for its Phase 3 trial, QUATRO-APL, testing QTX-2101 with ATRA for low-risk Acute Promyelocytic Leukemia treatment.
Why It Matters
The dosing of the first patient in a Phase 3 trial for a potential APL treatment signals progress in Quetzal Therapeutics' pipeline, which could lead to significant market opportunities and impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Atara Biotherapeutics announced the departure of Carol Gallagher, Pharm D, from its Board of Directors, expressing gratitude for her contributions to the company.
Why It Matters
Carol Gallagher's departure from Atara Biotherapeutics' Board could impact investor confidence, signaling potential shifts in strategy or governance at a key time for the company’s growth.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The Gross Law Firm advises Atara Biotherapeutics (NASDAQ: ATRA) shareholders to contact them for potential lead plaintiff roles related to a class period.
Why It Matters
Shareholder notices indicate potential legal issues, which can impact stock performance and investor sentiment regarding Atara Biotherapeutics.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Atara Biotherapeutics (NASDAQ: ATRA) for alleged securities violations. Affected investors from May 20, 2024, to January 9, 2026, should contact Schall Law Firm by May 22, 2026.
Why It Matters
The class action lawsuit against Atara Biotherapeutics for securities violations could lead to financial liability, impacting stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Faruqi & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics (NASDAQ: ATRA) and alerts investors of a May 22, 2026, deadline to join a federal securities class action.
Why It Matters
The investigation by Faruqi & Faruqi into Atara Biotherapeutics could indicate potential legal risks, affecting investor confidence and stock performance ahead of the class action deadline.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm announces a class action lawsuit for Atara Biotherapeutics (NASDAQ: ATRA) investors, covering securities purchased from May 20, 2024, to January 9, 2026.
Why It Matters
Class action lawsuits can impact stock prices and investor sentiment. Atara Biotherapeutics’ legal issues may affect its market performance and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ATRA Stock
What is Atara Biotherapeutics, Inc.'s (ATRA) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Atara Biotherapeutics, Inc. (ATRA) has a median price target of $13.00. The highest price target is $18.00 and the lowest is $10.00.
Is ATRA stock a good investment in 2027?
According to current analyst ratings, ATRA has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ATRA stock?
Wall Street analysts predict ATRA stock could reach $13.00 in the next 12 months. This represents a 49.9% increase from the current price of $8.67. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Atara Biotherapeutics, Inc.'s business model?
Atara Biotherapeutics operates by designing and developing cell and immunotherapies aimed at treating serious diseases, particularly in oncology. The company generates revenue through partnerships, collaborations with research institutions, and potentially from the commercialization of successful therapeutic candidates.
What is the highest forecasted price for ATRA Atara Biotherapeutics, Inc.?
The highest price target for ATRA is $18.00 from at , which represents a 107.6% increase from the current price of $8.67.
What is the lowest forecasted price for ATRA Atara Biotherapeutics, Inc.?
The lowest price target for ATRA is $10.00 from Ilya Zubkov at Freedom Broker, which represents a 15.3% increase from the current price of $8.67.
What is the overall ATRA consensus from analysts for Atara Biotherapeutics, Inc.?
The overall analyst consensus for ATRA is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are ATRA stock price projections?
Stock price projections, including those for Atara Biotherapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 5:23 AM UTC